Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight

The 7MM Sjögren's syndrome market is projected to expand through 2036, supported by approximately 3.3 million diagnosed prevalent cases in 2025 and a pipeline shifting from symptom management toward disease-modifying immunotherapies. Key near-term catalysts include Amgen's two Phase III dazodalibep trials expected to complete in H2 2026, Resolve Therapeutics' Phase II RSLV-132 study expected to complete in December 2026, and Vor Bio's global Phase III telitacicept topline data expected in H1 2027. Telitacicept received Chinese approval for adult Sjögren's disease in June 2026, while Novartis presented positive Phase III ianalumab data, reinforcing the commercial potential for targeted therapies in an underserved indication.

Analysis

The investable issue is not prevalence but conversion of a broad, heterogeneous diagnosis into a reimbursable moderate-to-severe treatment segment. First entrants with objective systemic-disease endpoints and biomarker-defined responder populations can command premium biologic pricing; therapies relying principally on dryness/fatigue patient-reported outcomes face materially higher placebo and payer-risk. Novartis appears best positioned for multiple expansion from a first-mover franchise, while Amgen's larger commercial platform makes Sjögren's financially incremental rather than thesis-changing.

Competitive differentiation will likely center on administration burden, infection/IgG-monitoring requirements, and whether efficacy is confined to seropositive/high-IgG patients. JNJ's biomarker signal is strategically valuable even if it narrows the addressable population: a credible precision-medicine label could improve response rates and facilitate reimbursement, but limits blockbuster assumptions. BMY's oral TYK2 exposure is the potential convenience disruptor only if it demonstrates systemic benefit; absent that, biologics with clearer disease-modifying evidence should retain specialist share.

Near-term catalysts are trial-data events rather than this market-research release. AMGN has the clearest 1-3 month calendar with two Phase III completions expected in H2 2026, while VOR's H1 2027 readout is a high-beta binary event; VOR also carries financing, execution, and ex-China bridging-risk that larger peers do not. The key falsifier across the group is failure to separate from placebo on validated systemic activity measures or a safety signal requiring restrictive monitoring, either of which would sharply reduce physician adoption and payer willingness to fund premium treatment.

Consensus may overstate a winner-take-all opportunity. Multiple immune mechanisms can coexist in Sjögren's, and successful launches may expand diagnosis and treatment intensity rather than simply displace each other; however, this also means sales forecasts based on diagnosed prevalence rather than severe, actively treated, biomarker-eligible patients are likely inflated. No broad sector trade is warranted from a promotional report without disclosed pricing, endpoint durability, and treated-population assumptions.

Key Decisions for Investors

• Maintain or initiate a modest long NVS / short BMY pair through the next meaningful ianalumab regulatory or launch update: NVS has the cleaner potential first-mover disease-modification narrative, while BMY's Sjögren's upside requires proof that an oral mechanism can deliver systemic efficacy. Target 8-12% relative upside over 6-12 months; exit if ianalumab labeling, payer access, or durability data are materially weaker than expected.
• Set an event-driven alert on AMGN ahead of H2 2026 Phase III data rather than buying the stock for this indication alone. Add only if disclosed endpoints show consistent efficacy across systemic-activity and symptom-dominant cohorts with acceptable safety; a positive result is likely modestly accretive to AMGN valuation, while a miss should create a limited, potentially buyable single-digit pullback given diversification.
• Treat VOR as a capped-risk binary watch position, not a core long, into the H1 2027 global Phase III topline. Any position should be sized assuming a 50%+ drawdown on an efficacy/safety miss or dilutive financing; upside requires evidence that China experience translates to Western trial endpoints and regulatory standards.
• Monitor JNJ for a formal high-IgG/autoantibody enrichment strategy. A prospectively validated biomarker-defined response would support incremental long exposure over 6-18 months; failure to replicate the exploratory subgroup result would remove the main differentiation versus broader B-cell pathway competitors.